Wednesday 20 April 2016

Dr. Reddy’s announced US availability of ZEMBRACE SymTouch

ZEMBRACE SymTouch is a prefilled, low-dose, ready-to-use, 2-step autoinjector containing 3 mg of sumatriptan, a selective 5-HT1B/ID receptor agonist. Because ZEMBRACE SymTouch is a subcutaneous injection, it may lead to rapid relief of migraine. 

Promius Pharma LLC, a subsidiary of Dr. Reddy’s Laboratories has announced that ZEMBRACE SymTouch is now commercially available in the U.S.

ZEMBRACE SymTouch is a prefilled, low-dose, ready-to-use, 2-step autoinjector containing 3 mg of sumatriptan, a selective 5-HT1B/ID receptor agonist. Because ZEMBRACE SymTouch is a subcutaneous injection, it may lead to rapid relief of migraine.

Migraineurs often have more than one kind of attack. Different types of medications can be used to treat different types of attacks. “ZEMBRACE SymTouch is a welcome addition to the toolkit for acute treatment of migraine” said Roger Cady, MD, Associate Executive Chairman of the National Headache Foundation.

“This 3-mg, easy to-use subcutaneous injection of sumatriptan may be desired by many migraine patients who need a medication that can rapidly treat migraine attacks. Also, the 3-mg dose allows for up to 4 doses of ZEMBRACE SymTouch in a 24-hour period, thus allowing dosing flexibility for patients,” added Cady. 

ZEMBRACE SymTouch is available as a box of 4 autoinjectors.

No comments:

Post a Comment